National Guideline Clearinghouse | The prognostic value of the DNMT3A biomarker in cytogenetically normal patients with acute myeloid leukemia.

full-text ►

National Guideline Clearinghouse | The prognostic value of the DNMT3A biomarker in cytogenetically normal patients with acute myeloid leukemia.



Program in Evidence-based Care

Cancer Care Ontario (CCO)

Guideline Title The prognostic value of the DNMT3A biomarker in cytogenetically normal patients with acute myeloid leukemia. Bibliographic Source(s) Leber B, Ismaila N, Kamel-Reid S, Rutherford M, Molecular Oncology Advisory Committee. The prognostic value of the DNMT3A biomarker in cytogenetically normal patients with acute myeloid leukemia. Toronto (ON): Cancer Care Ontario (CCO); 2013 Nov 27. 17 p. (Recommendation report; no. MOAC-1).  [23 references] Guideline Status This is the current release of the guideline. The RECOMMENDATION report, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities. Please visit the Cancer Care Ontario Web site  for details on any new evidence that has emerged and implications to the guidelines.